These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38341177)

  • 1. Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma.
    Logan A; Howard CB; Huda P; Kimpton K; Ma Z; Thurecht KJ; McCarroll JA; Moles E; Kavallaris M
    J Control Release; 2024 Mar; 367():806-820. PubMed ID: 38341177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
    McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
    Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
    Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
    Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
    Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
    J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
    Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
    Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.
    Reda M; Ngamcherdtrakul W; Gu S; Bejan DS; Siriwon N; Gray JW; Yantasee W
    Cancer Lett; 2019 Dec; 467():9-18. PubMed ID: 31563561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
    Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M
    Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.
    Hu K; Lee C; Qiu D; Fotovati A; Davies A; Abu-Ali S; Wai D; Lawlor ER; Triche TJ; Pallen CJ; Dunn SE
    Mol Cancer Ther; 2009 Nov; 8(11):3024-35. PubMed ID: 19887553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer.
    Moles E; Chang DW; Mansfeld FM; Duly A; Kimpton K; Logan A; Howard CB; Thurecht KJ; Kavallaris M
    Int J Nanomedicine; 2024; 19():3623-3639. PubMed ID: 38660023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
    Hu K; Law JH; Fotovati A; Dunn SE
    Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate-Mediated Targeted Delivery of siPLK1 by Leucine-Bearing Polyethylenimine.
    Hou L; Song Z; Xu Z; Wu Y; Shi W
    Int J Nanomedicine; 2020; 15():1397-1408. PubMed ID: 32184594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.
    Morry J; Ngamcherdtrakul W; Gu S; Reda M; Castro DJ; Sangvanich T; Gray JW; Yantasee W
    Mol Cancer Ther; 2017 Apr; 16(4):763-772. PubMed ID: 28138033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.
    Shi H; Sun S; Xu H; Zhao Z; Han Z; Jia J; Wu D; Lu J; Liu H; Yu R
    Int J Nanomedicine; 2020; 15():3347-3362. PubMed ID: 32494134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
    Gomes-da-Silva LC; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):356-64. PubMed ID: 23659854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
    Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
    Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells.
    Zhang C; Yuan W; Wu Y; Wan X; Gong Y
    Life Sci; 2021 Feb; 266():118886. PubMed ID: 33310044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
    Okamoto A; Asai T; Hirai Y; Shimizu K; Koide H; Minamino T; Oku N
    Mol Pharm; 2018 Apr; 15(4):1495-1504. PubMed ID: 29502423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.
    Yao YD; Sun TM; Huang SY; Dou S; Lin L; Chen JN; Ruan JB; Mao CQ; Yu FY; Zeng MS; Zang JY; Liu Q; Su FX; Zhang P; Lieberman J; Wang J; Song E
    Sci Transl Med; 2012 Apr; 4(130):130ra48. PubMed ID: 22517885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.